Concepedia

David K. Lau

DK

Statistics

Publications

5

Citations

134

H-Index

5

Active since

2019

Affiliations

Royal Marsden NHS Foundation Trust(Current)

Institute of Cancer Research

University of Surrey

University of Oxford

Royal Surrey NHS Foundation Trust

David K. Lau is an author at Royal Marsden NHS Foundation Trust specializing in radiation oncology, tumor biology, and tumor microenvironment.

ORCID

Top concepts

Publications per year

2019–2023

5

Publications

5

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study

David K. Lau, Eleftheria Kalaitzaki, David N. Church et al. · ESMO Open · 2020 · 66 citations · Full text

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

David K. Lau, Caroline Fong, F. Arouri et al. · BMC Cancer · 2023 · 21 citations · Full text

POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.

David K. Lau, David Cunningham, Angela Gillbanks et al. · Journal of Clinical Oncology · 2019 · 17 citations

, , +19

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK

David K. Lau, Ian Y. Luk, Laura J. Jenkins et al. · Molecular Cancer Therapeutics · 2021 · 17 citations · Full text

Genetic and immune landscape evolution in <scp>MMR‐</scp> deficient colorectal cancer

Benjamin Challoner, Andrew Woolston, David K. Lau et al. · The Journal of Pathology · 2023 · 13 citations · Full text

1–5 of 5